(1) The year ended December 31, 2023 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards ...

(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share ...

HOUSTON, July 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2025 revenue of ...

Wide-moat Core Laboratories posted third-quarter results mostly in line with our estimates. Revenue of $134 million was up 3% sequentially and 7% year over year, while operating income of $20 million ...

HOUSTON, May 7, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") is pleased to announce the opening of its new Unconventional Core Analysis Laboratory ...

probability of performance condition for certain executive's share awards. (2) Three months ended June 30, 2025 and September 30, 2025 includes the write-down of inventory. (3) Three months ended June ...